AR076495A1 - Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso - Google Patents

Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso

Info

Publication number
AR076495A1
AR076495A1 ARP100101450A ARP100101450A AR076495A1 AR 076495 A1 AR076495 A1 AR 076495A1 AR P100101450 A ARP100101450 A AR P100101450A AR P100101450 A ARP100101450 A AR P100101450A AR 076495 A1 AR076495 A1 AR 076495A1
Authority
AR
Argentina
Prior art keywords
sulfated
fragments
monoclonal antibodies
antibodies
proteoglycans
Prior art date
Application number
ARP100101450A
Other languages
English (en)
Inventor
Requena Alejandro Lopez
Marrero Yuniel Fernandez
Lopez Yosdel Soto
Navarro Victor Brito
Lopez Ana Maria Vazquez
De Acosta Del Rio Cristina Mateo
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42355373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076495(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of AR076495A1 publication Critical patent/AR076495A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Está relacionada con el campo de la biotecnología y particularmente con nuevos productos para ser usados en la salud humana. Se proporcionan anticuerpos monoclonales que reconocen de manera específica y con alta afinidad sulfátidos y proteoglicanos sulfatados. Los anticuerpos anti-sulfátidos y anti-proteoglicanos sulfatados descritos en la presente memoria descriptiva, proporcionan agentes diagnosticos y terapéuticos para actuar sobre procesos patologicos asociados a la aparicion de placas ateroscleroticas. Segun esto, se proporcionan composiciones farmacéuticas que comprenden los anticuerpos monoclonales o los fragmentos derivados de estos anticuerpos para su uso terapéutico y diagnostico asociado a enfermedades cardiovasculares. Adicionalmente se relaciona con los fragmentos de los anticuerpos monoclonales que reconocen sulfátidos y proteoglicanos sulfatados, de modo que dichos fragmentos puedan ser usados en la terapia o el diagnostico de esta patología.
ARP100101450A 2009-05-04 2010-04-29 Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso AR076495A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20090071A CU23736A1 (es) 2009-05-04 2009-05-04 Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso

Publications (1)

Publication Number Publication Date
AR076495A1 true AR076495A1 (es) 2011-06-15

Family

ID=42355373

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101450A AR076495A1 (es) 2009-05-04 2010-04-29 Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso

Country Status (21)

Country Link
US (1) US8470322B2 (es)
EP (1) EP2428521B1 (es)
JP (1) JP5354823B2 (es)
KR (1) KR101374263B1 (es)
CN (1) CN102414222B (es)
AR (1) AR076495A1 (es)
AU (1) AU2010244859B2 (es)
BR (1) BRPI1013991B1 (es)
CA (1) CA2758994C (es)
CL (1) CL2010000413A1 (es)
CU (1) CU23736A1 (es)
ES (1) ES2656849T3 (es)
HK (1) HK1168362A1 (es)
MX (1) MX2011011665A (es)
MY (1) MY158954A (es)
PE (1) PE20100808A1 (es)
RU (1) RU2502744C2 (es)
SG (1) SG175849A1 (es)
TW (1) TWI424852B (es)
WO (1) WO2010127642A1 (es)
ZA (1) ZA201108832B (es)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770198A (en) 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5196324A (en) 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
US20020018808A1 (en) 1990-12-10 2002-02-14 Alving Carl R. Vaccines against sterols
US5541296A (en) 1991-08-30 1996-07-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Monocyte adhesion protein and monoclonal antibody thereto
US6471965B1 (en) 1994-07-27 2002-10-29 Bio-Virus Research Incorporated Vaccine containing whole killed herpes viruses to prevent development of atherosclerotic plaque
JP4315257B2 (ja) * 1995-11-13 2009-08-19 生化学工業株式会社 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするｄｎａおよびそれに対する抗体
WO1997041227A1 (en) 1996-05-01 1997-11-06 T Cell Sciences, Inc. Plasmid-based vaccine for treating atherosclerosis
EP0964686A4 (en) 1996-08-14 2000-10-18 Wistar Inst METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING THE DEVELOPMENT OF ATHEROSCLERIC LESIONS
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
WO1999052551A1 (en) 1998-04-15 1999-10-21 King's College London Therapy of atherosclerosis
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US20030100508A1 (en) * 1999-02-24 2003-05-29 Maryline Simon Carbohydrate epitope mimic compounds and uses thereof
JP2003525883A (ja) 2000-03-03 2003-09-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
SE0000855D0 (sv) 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
GB0121171D0 (en) 2001-08-31 2001-10-24 Glaxosmithkline Biolog Sa Vaccine
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
GB0305793D0 (en) 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
GB0305794D0 (en) 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
GB0305790D0 (en) 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Novel Composition
WO2004091520A2 (en) 2003-04-11 2004-10-28 The Regents Of The University Of California Methods and compositions for treating atherosclerosis
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
SE0302422D0 (sv) 2003-09-11 2003-09-11 Forskarpatent I Syd Ab Peptide-based immunization therapy for treatment of atherosclerosis
DE602005020474D1 (de) 2004-04-15 2010-05-20 Athera Biotechnologies Ab Antikörper gegen Phosphorylcholinkonjugate
US20060276400A1 (en) 2005-06-06 2006-12-07 Hedy Adari Modulation of cholesteryl ester transfer protein (CETP) activity
FR2906533B1 (fr) * 2006-09-28 2013-02-22 Pf Medicament Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations

Also Published As

Publication number Publication date
KR101374263B1 (ko) 2014-03-13
RU2502744C2 (ru) 2013-12-27
TW201103559A (en) 2011-02-01
AU2010244859B2 (en) 2014-05-29
AU2010244859A1 (en) 2011-12-08
MX2011011665A (es) 2012-06-01
JP2012526056A (ja) 2012-10-25
US20120121605A1 (en) 2012-05-17
CN102414222A (zh) 2012-04-11
ZA201108832B (en) 2012-08-29
BRPI1013991B1 (pt) 2021-08-31
PE20100808A1 (es) 2011-01-07
US8470322B2 (en) 2013-06-25
JP5354823B2 (ja) 2013-11-27
WO2010127642A9 (es) 2011-03-24
EP2428521A1 (en) 2012-03-14
SG175849A1 (en) 2011-12-29
BRPI1013991A2 (pt) 2016-04-05
CU23736A1 (es) 2011-11-15
TWI424852B (zh) 2014-02-01
MY158954A (en) 2016-11-30
EP2428521B1 (en) 2018-01-03
CN102414222B (zh) 2014-07-16
KR20120016055A (ko) 2012-02-22
WO2010127642A1 (es) 2010-11-11
RU2011149252A (ru) 2013-06-10
CL2010000413A1 (es) 2011-02-25
CA2758994A1 (en) 2010-11-11
ES2656849T3 (es) 2018-02-28
CA2758994C (en) 2015-07-21
HK1168362A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
WO2011045415A3 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
BR112015023333A2 (pt) pirrolobenzodiazepinas e conjugados das mesmas
ECSP13012609A (es) Composición farmacéutica
CR20140394A (es) Anticuerpo monoclonal
BRPI0911518A2 (pt) novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao estresse de célula
AR077333A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina -2 humana
BRPI0810081A2 (pt) Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial
BR112014018561A8 (pt) Anticorpo; ácido nucleico; célula hospedeira; composição farmacêutica; uso de um anticorpo; método para produção de um anticorpo; e método para produção de uma linhagem celular que produz um anticorpo
CU20110031A7 (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
CR20130313A (es) Anticuerpos anti-cd38
UA107600C2 (uk) АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ
BRPI0911520A2 (pt) novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de angiogênese.
PH12014502399A1 (en) Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
CO6450654A2 (es) Identificación de moléculas pequeñas reconocidas por anticuerpos en sujetos con enfermedades neurodegenerativas
NO20075527L (no) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
BR112015021908A2 (pt) implante
BR112013020265A2 (pt) formas de rifaximina e uso das mesmas
AR071304A1 (es) Anticuerpos anti cd151 (proteina de membrana de la flia. de las tetraspaninas) utiles para el tratamiento de cancer
BR112014014960A2 (pt) métodos para o diagnóstico da doença de alzheimer
BRPI0906492A2 (pt) antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações
BR112013016107A2 (pt) molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar
IL203130A (en) Variants of 44 cd splicing products for the diagnosis and treatment of neurodegenerative diseases
BR112015027249A2 (pt) método de diagnóstico de câncer
FR3013956B1 (fr) Methode d'evaluation in vivo de l'etat physiopathologique d'un tissu biologique et dispositif associe
AR076495A1 (es) Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso

Legal Events

Date Code Title Description
FG Grant, registration